Cities exhibit consistent returns to scale in economic outputs, and urban scaling analysis is widely adopted to uncover common mechanisms in cities' socioeconomic productivity. Leading theories view cities as closed systems, with returns to scale arising from intra-city social interactions. Here, we argue that the interactions between cities, particularly via shared organizations such as firms, significantly influence a city's economic output.
View Article and Find Full Text PDFVascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer survival but are associated with treatment-limiting hypertension, often attributed to endothelial cell (EC) dysfunction. Using phosphoproteomic profiling of VEGFRi-treated ECs, drugs were screened for mitigators of VEGFRi-induced EC dysfunction and validated in primary aortic ECs, mice, and canine cancer patients. VEGFRi treatment significantly raised systolic blood pressure (SBP) and increased markers of endothelial and renal dysfunction in mice and canine cancer patients.
View Article and Find Full Text PDFAcetyl-Coenzyme A is a central metabolite in catabolic and anabolic pathways as well as the acyl donor for acetylation reactions. Multiple quantitative measurement techniques for acetyl-CoA have been reported, including commercially available kits. Comparisons between techniques for acetyl-CoA measurement have not been reported.
View Article and Find Full Text PDFChemotherapy-induced impairment of autophagy is implicated in cardiac toxicity induced by anti-cancer drugs. Imperfect translation from rodent models and lack of in vitro models of toxicity has limited investigation of autophagic flux dysregulation, preventing design of novel cardioprotective strategies based on autophagy control. Development of an adult heart tissue culture technique from a translational model will improve investigation of cardiac toxicity.
View Article and Find Full Text PDFPurpose Of Review: While vascular endothelial growth factor receptor inhibitors (VEGFRis) have dramatically improved cancer survival, these drugs cause hypertension in a majority of patients. This side effect is often dose limiting and increases cardiovascular mortality in cancer survivors. This review summarizes recent advances in our understanding of the molecular mechanisms and clinical findings that impact management of VEGFRi-induced hypertension.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
August 2021
J Vet Emerg Crit Care (San Antonio)
March 2021